{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:59:55Z","timestamp":1787317195928,"version":"build-2736575974"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Based on the notion that inflammation plays a pivotal role in the development and progression of cardiovascular diseases (CV) and that hyperuricaemia is an independent CV risk factor, chronic inflammatory diseases such as gout and rheumatoid arthritis are an interesting case study. Both conditions are burdened by an excess CV risk; they are themselves an independent CV risk factor, and in the case of gout, hyperuricaemia is a hallmark of the disease. Colchicine, a drug historically used for the management of gout, has recently been repurposed for secondary CV prevention in individuals at high CV risk. The purpose of this review article is to discuss evidence on CV diseases and CV prevention in rheumatoid arthritis, gout, and other chronic inflammatory\/systemic autoimmune diseases with a focus on inflammation and hyperuricaemia.<\/jats:p>","DOI":"10.3390\/metabo15070424","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:23:24Z","timestamp":1750418604000},"page":"424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uric Acid, Colchicine and Chronic Inflammatory Diseases: A Cardiovascular Perspective"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5640","authenticated-orcid":false,"given":"Alessia","family":"Alunno","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Life, Health and Environmental Sciences, Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L\u2019Aquila, San Salvatore Hospital, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-5136","authenticated-orcid":false,"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Life, Health and Environmental Sciences, Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L\u2019Aquila, San Salvatore Hospital, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-2503","authenticated-orcid":false,"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Life, Health and Environmental Sciences, Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L\u2019Aquila, San Salvatore Hospital, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: Mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e026677","DOI":"10.1136\/bmjopen-2018-026677","article-title":"Diagnosis and treatment for hyperuricemia and gout: A systematic review of clinical practice guidelines and consensus statements","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC Scientific Document Group; 2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: Rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"152389","DOI":"10.1016\/j.semarthrit.2024.152389","article-title":"The management of cardiovascular risk in psoriatic disease: A bridge over troubled water","volume":"65","author":"Alunno","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/1756-185X.13811","article-title":"The burden of subclinical intra-articular inflammation in gout","volume":"23","author":"Chowalloor","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jjcc.2020.12.013","article-title":"Uric acid and cardiovascular disease: A clinical review","volume":"78","author":"Saito","year":"2021","journal-title":"J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shubietah, A., Awashra, A., Milhem, F., Ghannam, M., Hattab, M., Rajab, I., Neiroukh, H., Zahdeh, M., Nouri, A., and Assaassa, A. (2025). Hyperuricemia and Cardiovascular Risk: Insights and Implications. Crit. Pathw. Cardiol.","DOI":"10.1097\/HPC.0000000000000388"},{"key":"ref_11","first-page":"4198","article-title":"Serum uric acid levels and risk of metabolic syndrome: A dose\u2013response meta-analysis of prospective studies. J. Clin. Endocrinol","volume":"100","author":"Yuan","year":"2015","journal-title":"Metabolism"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension; Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/HJH.0000000000002589","article-title":"Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Serum uric acid, predicts heart failure in a large Italian cohort: Search for a cut-off value the URic acid Right for heArt Health study","volume":"39","author":"Muiesan","year":"2021","journal-title":"J. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ying, H., Yuan, H., Tang, X., Guo, W., Jiang, R., and Jiang, C. (2021). Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.641062"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): A multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ye, Y., Liao, G., Liu, T., Hu, X., Chen, X., Bai, L., and Peng, Y. (2023). Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10090379"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy Randomized Controlled Trial","volume":"40","author":"Kijima","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/14656566.2023.2197591","article-title":"Advances in pharmacotherapies for hyperuricemia","volume":"24","author":"Piani","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/dom.15157","article-title":"Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials","volume":"25","author":"Banerjee","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"15","author":"You","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e003836","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: A systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2024","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week","volume":"83","author":"Packer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: From mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_24","first-page":"II2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"CANTOS trial group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"CIRT investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"Design of the ZEUS trial: Interleukin 6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"LoDoCo2 trial investigators. Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","unstructured":"(2025, June 19). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215727s000lbl.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"van der Pol, K.H., Wever, K.E., Verbakel, M., Visseren, F.L.J., Cornel, J.H., and Rongen, G.A. (2021). Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260844"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"CARES Investigators Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"FAST study group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.mayocp.2019.03.001","article-title":"Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study","volume":"94","author":"Su","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat Versus Allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10067-025-07386-z","article-title":"Association between rheumatoid arthritis and hyperuricemia among adults: A cross-sectional study based on NHANES data","volume":"44","author":"Zhao","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.jhh.1002298","article-title":"Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis","volume":"22","author":"Panoulas","year":"2008","journal-title":"J. Hum. Hypertens."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/kem159","article-title":"Association of serum uric acid with cardiovascular disease in rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"523897","DOI":"10.1155\/2014\/523897","article-title":"Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis","volume":"2014","author":"Kuo","year":"2014","journal-title":"Int. J. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/acr.23926","article-title":"Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations with Comorbidities, Disease Activity, and Mortality","volume":"72","author":"Chiou","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lyngdoh, T., Marques-Vidal, P., Paccaud, F., Preisig, M., Waeber, G., Bochud, M., and Vollenweider, P. (2011). Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019901"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200808-1274OC","article-title":"Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis","volume":"179","author":"Gasse","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2014.115","article-title":"Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis","volume":"10","author":"Catrina","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103614","DOI":"10.1016\/j.autrev.2024.103614","article-title":"Cardiovascular disease in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis of observational studies","volume":"23","author":"Hu","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.amjms.2025.02.006","article-title":"Associations between psoriasis, psoriatic arthritis and gout or hyperuricemia: A systematic review and meta-analysis","volume":"369","author":"Liu","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e17643","DOI":"10.1097\/MD.0000000000017643","article-title":"The association of serum uric acid levels in psoriasis patients: A systematic review and network meta-analysis","volume":"98","author":"Yuan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E1255","DOI":"10.1152\/ajpendo.00214.2013","article-title":"The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis","volume":"305","author":"Petrie","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00296-024-05729-8","article-title":"Understanding the interplay between psoriatic arthritis and gout: \u201cPsout\u201d","volume":"44","author":"Sherri","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semarthrit.2008.06.001","article-title":"Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease","volume":"39","author":"Martin","year":"2009","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3899\/jrheum.170384","article-title":"Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia","volume":"45","author":"AlJohani","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_56","unstructured":"Wise, E., Lewis, E., Khanna, P., Zhao, L., and McCune, W.J. (2015, January 6\u201311). A Strong Association Between Gout and Diuretic Use Among Lupus Patients. Proceedings of the 2015 ACR\/ARHP Annual Meeting, San Francisco, CA, USA."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00296-010-1373-x","article-title":"Association of serum uric acid with lupus nephritis in systemic lupus erythematosus","volume":"31","author":"Yang","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1007\/s10067-019-04620-3","article-title":"Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?","volume":"38","author":"Gavinier","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e000366","DOI":"10.1136\/lupus-2019-000366","article-title":"Serum uric acid is associated with damage in patients with systemic lupus erythematosus","volume":"7","author":"Medina","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mvr.2016.03.007","article-title":"Serum uric acid as a marker of microvascular damage in systemic sclerosis patients","volume":"106","author":"Gigante","year":"2016","journal-title":"Microvasc. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Alunno, A., Carubbi, F., Mariani, F.M., Martini, C., Campanozzi, E., and Ferri, C. (2023). The Interplay between Cardiovascular Risk, Cardiovascular Events, and Disease Activity in Primary Sj\u00f6gren\u2019s Syndrome: Is Uric Acid the Missing Link?. Nutrients, 15.","DOI":"10.3390\/nu15071563"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/gucdd2020011","article-title":"Circadian Rhythms in NLRP3 Inflammasome Regulation: Possible Implications for the Nighttime Risk of Gout Flares","volume":"2","author":"Poulsen","year":"2024","journal-title":"Gout Urate Cryst. Depos. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jacob, H., Curtis, A.M., and Kearney, C.J. (2020). Therapeutics on the clock: Circadian medicine in the treatment of chronic inflammatory diseases. Biochem. Pharmacol., 182.","DOI":"10.1016\/j.bcp.2020.114254"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients with Gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","article-title":"Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: A retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2023.12.028","article-title":"Colchicine and cardiovascular prevention","volume":"121","author":"Alunno","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejim.2023.12.027","article-title":"A systematic literature review of randomised controlled trials evaluating colchicine for cardiovascular prevention: There is an elephant in the room","volume":"125","author":"Alunno","year":"2024","journal-title":"Eur. J. Intern. Med."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/7\/424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:55Z","timestamp":1760032555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/7\/424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["metabo15070424"],"URL":"https:\/\/doi.org\/10.3390\/metabo15070424","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}